Y-mAbs Therapeutics (NASDAQ:YMAB) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a note issued to investors on Friday, The Fly reports.
A number of other equities research analysts have also recently weighed in on YMAB. JPMorgan Chase & Co. restated an “overweight” rating and set a $52.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 29th. Zacks Investment Research cut Y-mAbs Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 24th. HC Wainwright raised their target price on Y-mAbs Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 8th. Finally, Wedbush dropped their target price on shares of Y-mAbs Therapeutics from $67.00 to $52.00 and set an “outperform” rating on the stock in a report on Wednesday, April 21st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $54.38.
YMAB stock traded up $4.93 on Friday, hitting $33.58. 13,152 shares of the company were exchanged, compared to its average volume of 296,491. Y-mAbs Therapeutics has a twelve month low of $24.77 and a twelve month high of $55.22. The business’s fifty day moving average is $29.47 and its two-hundred day moving average is $41.50. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -11.31 and a beta of 1.36.
Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Thursday, May 6th. The company reported $0.75 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.14. Sell-side analysts predict that Y-mAbs Therapeutics will post -3.25 earnings per share for the current year.
In other news, insider Thomas Gad sold 7,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, March 15th. The shares were sold at an average price of $36.79, for a total transaction of $257,530.00. Following the transaction, the insider now owns 7,000 shares in the company, valued at $257,530. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 21,000 shares of company stock valued at $639,520 in the last ninety days. Company insiders own 38.40% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in YMAB. Penserra Capital Management LLC raised its stake in shares of Y-mAbs Therapeutics by 171.9% in the fourth quarter. Penserra Capital Management LLC now owns 930 shares of the company’s stock worth $46,000 after purchasing an additional 588 shares during the last quarter. Pacer Advisors Inc. grew its stake in Y-mAbs Therapeutics by 137.2% during the first quarter. Pacer Advisors Inc. now owns 1,812 shares of the company’s stock valued at $55,000 after acquiring an additional 1,048 shares in the last quarter. Amalgamated Bank bought a new stake in Y-mAbs Therapeutics during the fourth quarter valued at $236,000. Aperio Group LLC grew its position in Y-mAbs Therapeutics by 8.9% in the fourth quarter. Aperio Group LLC now owns 5,685 shares of the company’s stock worth $281,000 after acquiring an additional 464 shares in the last quarter. Finally, Susquehanna International Group LLP raised its stake in shares of Y-mAbs Therapeutics by 28.2% during the fourth quarter. Susquehanna International Group LLP now owns 6,815 shares of the company’s stock worth $337,000 after acquiring an additional 1,501 shares in the last quarter. 53.20% of the stock is currently owned by hedge funds and other institutional investors.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
Further Reading: Guidelines for Successful Channel Trading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: What is a stock split?
7 Bellwether Stocks Signaling a Return to Normal
Bellwether stocks are considered to be leading indicators about the direction of the overall economy, a specific sector, or the broader market. They are predictive stocks in that investors can use the company’s earnings reports to gauge economic strength or weakness.
The traditional definition of bellwether stocks brings to mind established, blue-chip companies. They are the home of mature brands with consumer loyalty. These may be stocks that aren’t associated with exceptional growth; some may be dividend stocks.
But there’s something different about normal this time around. If it’s true (and I think it is) that the old rules no longer apply, investors need to change the way they think about bellwether stocks. Plus, let’s face it, many stocks that we might consider to be bellwether stocks have already had a bit of a vaccine rally. That means that the easy gains are gone.
With that in mind, we’ve put together this special presentation that highlights seven of what may be termed the new bellwether stocks. These are stocks that investors should be paying attention to as the economy continues to reopen.
One quality of many of these stocks is that they are either negative for 2021 or underperforming the broader market. And that means that they are likely to have a strong upside as the economy grows.
View the “7 Bellwether Stocks Signaling a Return to Normal”.